Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?

IL-23i such as guselkumab have not really shown a significantly higher incidence of infections or malignancies, so I would favor these over other biologics. Ustekinumab (IL-12,23i) also showed lower rates of infection compared with other biologics. However, something to consider is whether they have...